Supplemental material
OncoImmunology
Volume 8, 2019 - Issue 7
Original Research
A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system
, , , , , , , , & 
show all
Gilles MarodonCNRS, INSERM U1135, Centre d’Immunologie et des Maladies Infectieuses, CIMI, Sorbonne Université, Paris, FranceCorrespondence[email protected]
https://orcid.org/0000-0003-4889-6785View further author information
https://orcid.org/0000-0003-4889-6785View further author information show allRelated Research Data
Cellular immune response
Source:
Wiley
Unique expression of ICOS on TREGS in gastric cancer
Source:
Wiley
Nivolumab plus Ipilimumab in Advanced Melanoma
Source:
Massachusetts Medical Society
Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.
Source:
American Association for Cancer Research (AACR)
Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Source:
American Association for Cancer Research (AACR)
XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer.
Source:
Springer Science and Business Media LLC
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
Source:
HAL CCSD
ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells
Source:
American Association for Cancer Research (AACR)
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Source:
American Association for Cancer Research (AACR)
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
Source:
Elsevier BV
Development and function of human innate immune cells in a humanized mouse model
Source:
Nature Publishing Group
Humanized tumor mice--a new model to study and manipulate the immune response in advanced cancer therapy.
Source:
Wiley-Blackwell
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
Source:
Rockefeller University Press
ICOS promotes the function of CD4+ effector T cells during anti-OX40 mediated tumor rejection
Source:
American Association for Cancer Research (AACR)
A Systematic Review
Source:
American Medical Association (AMA)
Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells
Source:
American Association for Cancer Research (AACR)
ICOS Co-Stimulation: Friend or Foe?
Source:
Frontiers Media SA
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Source:
Rockefeller University Press
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Source:
Springer Science and Business Media LLC
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model
Source:
Taylor & Francis
The role of ICOS in directing T cell responses: ICOS-dependent induction of T cell anergy by tolerogenic dendritic cells.
Source:
The American Association of Immunologists
Humanized Mouse Xenograft Models: Narrowing the Tumor–Microenvironment Gap
Source:
American Association for Cancer Research (AACR)
Linking provided by
